Drug Price Reporting Rules Foiled by Loopholes in Supply Chain
The PBM industry counters that it shouldn’t have to report anything. The Pharmaceutical Care Management Association, which represents PBMs, said in its comment letter that the rule goes beyond the agencies’ statutory authority and asked that “amounts retained by PBMs” be excluded. “As a form of PBM compensation, amounts retained by PBMs and not passed through to the plan have a net-zero impact on premiums,” it said.